SLEEP® journal paper shows Oventus ExVentTM and OnePAPTM valves used in combination with mandibular advancement splints like O2Vent® reduce sleep apnoea for a substantial proportion of patients
Brisbane, Australia 13 June 2019: Oventus Medical Ltd (ASX: OVN) is pleased to advise that a peer-reviewed paper on Oventus’ clinical data has been published in the scientific journal, SLEEP® this week. The paper demonstrates how Oventus’ O2Vent® mandibular advancement splint (MAS), used in combination with valves such as the ExVentTM* and O2Vent® OnePAPTM*, reduces the severity of Obstructive Sleep Apnoea (OSA) to therapeutic levels for a substantial proportion of incomplete/non-responder patients, compared to MAS therapy alone.
For further information please download the attached PDF:
Download this document
